A PYMNTS Company

Roche receives FTC second request for proposed acquisition of Illumina

By  |  March 13, 2012

Roche has announced that the FTC has issued a second request for information on its proposed acquisition of Illumina. Under the terms of the tender offer, Roche will purchase all outstanding shares of Illumina for $44.50 in cash. Switzerland-based Roche is the world’s largest biotech company. The request concerns Roche’s microarray business. The Hart-Scott-Rodino waiting period will be delayed until 10 days after Roche has substantially complied with the second request.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full content: Marketwatch

     

    Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)